WO2000016061B1 - Method for diagnosing the active stage of a cytomegalovirus infection in human substrates - Google Patents

Method for diagnosing the active stage of a cytomegalovirus infection in human substrates

Info

Publication number
WO2000016061B1
WO2000016061B1 PCT/RU1999/000246 RU9900246W WO0016061B1 WO 2000016061 B1 WO2000016061 B1 WO 2000016061B1 RU 9900246 W RU9900246 W RU 9900246W WO 0016061 B1 WO0016061 B1 WO 0016061B1
Authority
WO
WIPO (PCT)
Prior art keywords
cytomegalovirus
active stage
infection
diagnosing
anτigena
Prior art date
Application number
PCT/RU1999/000246
Other languages
French (fr)
Russian (ru)
Other versions
WO2000016061A2 (en
WO2000016061A3 (en
Inventor
Anatoly Jurievich Zvonarev
Igor Zakvanovich Zaitsev
Tengiz Dmitrievi Shalamberidze
Original Assignee
Unitarnoe G Mo Predpr Proizv B
Anatoly Jurievich Zvonarev
Igor Zakvanovich Zaitsev
Tengiz Dmitrievi Shalamberidze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unitarnoe G Mo Predpr Proizv B, Anatoly Jurievich Zvonarev, Igor Zakvanovich Zaitsev, Tengiz Dmitrievi Shalamberidze filed Critical Unitarnoe G Mo Predpr Proizv B
Priority to AU11918/00A priority Critical patent/AU1191800A/en
Publication of WO2000016061A2 publication Critical patent/WO2000016061A2/en
Publication of WO2000016061A3 publication Critical patent/WO2000016061A3/en
Publication of WO2000016061B1 publication Critical patent/WO2000016061B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention pertains to the field of virology and relates to an express diagnosis for viral infections. This invention essentially relates to a method for diagnosing the active stage of cytomegalovirus infection in a patient, wherein said method involves carrying out a sorption of the specific antigen in solid phase, adding the serum to be analysed, carrying out an incubation using a conjugate of immunologic ferments as well as a substrate and estimating the results. The antigen consists of the recombinant, main, precursor and non-structured protein of the cytomegalovirus, and the active stage of the infection is detected upon the occurrence of antibodies against said cytomegalovirus.

Claims

00/16061 ΡСΤ/ΚΙΙ99/00246ИЗΜΕΗЁΗΗΑЯ ΦΟΡΜУЛΑ ИЗΟБΡΕΤΕΗИЯ[ποлучена Μеждунаροдным бюρο 15 φевρаля 2000 (15.02.00); πеρвοначальнο πеρвοначальнο заявленные πунκτы 1-2 φορмулы изοбρеτения заменены изменёнными πунκτами 1-2 (1 сτρаница)] 00/16061 ΡСΤ / ΚΙΙ99 / 00246 ΜΕΗΟΡΜΜΕΗΑ ΟΡΜΟΡΜΑΑ ΑΟΟ [[received by the International Bureau on 15 February 2000 (02.15.00); Paragraphs 1-2 of the original claims are replaced by the modified paragraphs 1-2 (1 page)]
1. Сποсοб οπρеделения аκτивнοй сτадии циτοмегалοвиρуснοй инφеκции в челοве- чесκиχ субсτρаτаχ , вκлючающий сορбцию сπециφичесκοгο анτигена на τвеρдую φазу, внесение исπыτуемοй сывοροτκи, инκубацию с иммунοφеρменτным κοнъ- югаτοм и субсτρаτοм с ποследующей οценκοй ρезульτаτοв, οτличающийся τем, чτο в κачесτве анτигена исποльзуюτ ρеκοмбинанτный οснοвнοй πρедρанний не- сτρуκτуρный белοκ циτοмегалοвйρуса, и πρи выявлении анτиτел κ нему деτеκ- τиρуюτ аκτивную сτадию инφеκции.1. Sποsοb οπρedeleniya aκτivnοy sτadii tsiτοmegalοviρusnοy inφeκtsii in chelοve- chesκiχ subsτρaτaχ, vκlyuchayuschy sορbtsiyu sπetsiφichesκοgο anτigena on τveρduyu φazu, making isπyτuemοy syvοροτκi, inκubatsiyu with immunοφeρmenτnym κοn- yugaτοm and subsτρaτοm with ποsleduyuschey οtsenκοy ρezulτaτοv, οτlichayuschiysya τem, chτο in κachesτve anτigena isποlzuyuτ ρeκοmbinanτny οsnοvnοy πρedρanny inadequate protein of cytomegalovirus, and in case of detection of antibodies to it, they deactivate an active stage of infection.
2. Сποсοб πο π.1, οτличающийся τем, чτο исποльзуюτ ρеκοмбинанτный οснοвнοй πρедρанний несτρуκτуρный белοκ циτοмегалοвиρуса челοвеκа, κлοниροванный и эκсπρессиροванный в белοκ-синτезиρующей сисτеме Ε.сοН.2. The method of π.1, which is distinguished by the fact that it uses a commercially available non-regular white non-obese and whitewashed white person.
ИЗΜΕΗЁΗΗЫЙ ЛИСΤ (СΤΑΤЬЯ 19) LIQUID FOX (SΤJA 19)
PCT/RU1999/000246 1998-09-16 1999-07-22 Method for diagnosing the active stage of a cytomegalovirus infection in human substrates WO2000016061A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11918/00A AU1191800A (en) 1998-09-16 1999-07-22 Method for diagnosing the active stage of a cytomegalovirus infection in a person

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU98117062 1998-09-16
RU98117062A RU2133472C1 (en) 1998-09-16 1998-09-16 Method for diagnosing active stage of human cytomegalovirus infection

Publications (3)

Publication Number Publication Date
WO2000016061A2 WO2000016061A2 (en) 2000-03-23
WO2000016061A3 WO2000016061A3 (en) 2000-06-02
WO2000016061B1 true WO2000016061B1 (en) 2000-07-06

Family

ID=20210421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1999/000246 WO2000016061A2 (en) 1998-09-16 1999-07-22 Method for diagnosing the active stage of a cytomegalovirus infection in human substrates

Country Status (3)

Country Link
AU (1) AU1191800A (en)
RU (1) RU2133472C1 (en)
WO (1) WO2000016061A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
MX343490B (en) 2008-07-16 2016-11-08 Inst For Res In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3619902A1 (en) * 1986-06-13 1988-03-03 Biotechnolog Forschung Gmbh CMV DNA STRUCTURES, EXPRESSION VECTOR DAFUER, CMV PROTEIN STRUCTURES AND THEIR USE
ZA878031B (en) * 1986-11-04 1988-04-28 Scripps Clinic And Research Foundation Nucleic acid probes for the detection of latent human cytomegalovirus in blood products
US5180813A (en) * 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
RU2028156C1 (en) * 1991-02-15 1995-02-09 Научно-исследовательский институт вирусных препаратов РАМН Method of immunosorbent preparing for diagnosis of cytomegaloviral infection

Also Published As

Publication number Publication date
RU2133472C1 (en) 1999-07-20
AU1191800A (en) 2000-04-03
WO2000016061A2 (en) 2000-03-23
WO2000016061A3 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
Grauballe et al. Optimized enzyme‐linked immunosorbent assay for detection of human and bovine rotavirus in stools: Comparison with electron‐microscopy, immunoelectro‐osmophoresis, and fluorescent antibody techniques
Meytes et al. Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group
CA2270995A1 (en) Improvements in or relating to screening for papilloma viruses
Coltorti et al. Detection of antibodies against Echinococcus granulosus arc 5 antigens by double diffusion test
EP0248534A3 (en) Method of detecting aids virus infection
CA2393127A1 (en) Diagnostic assay for stroke
US20030152919A1 (en) Method and compositions for use in diagnosing and characterizing chronic immune disease
Fekadu et al. Use of the avidin-biotin peroxidase system to detect rabies antigen in formalin-fixed paraffin-embedded tissues
Rickard Serological diagnosis and post-operative surveillance of human hydatid disease. l. latex agglutination and immunoelectrophoresis using crude cyst fluid antigen
CA2236554A1 (en) Immunoassay for determining the avidity of immunoglobulins
WO2000016061B1 (en) Method for diagnosing the active stage of a cytomegalovirus infection in human substrates
EP0869177A3 (en) Human a- and b- platelet-derived growth factor receptor proteins and uses therefor.
Alderete et al. Soluble Trichomonas vaginalis antigens in cell-free culture supernatants
ATE147410T1 (en) IGM ANTIBODIES AGAINST PROTAMIN
Saz et al. Enzyme-linked immunosorbent assay for diagnosis of brucellosis
US20100267009A1 (en) Method for the in vitro diagnosis and/or in vitro therapy monitoring of infections
Raux et al. Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients
Visintini et al. Immunological studies in cluster headache and migraine
WO2003046563A1 (en) Food intolerance immunoassay
JP3895262B2 (en) Hepatitis C disease test method
JPH11503524A (en) HIV-TAT detection method
JP2003502643A (en) Assay
WO2020058213A1 (en) Process for increasing the sensitivity of an immunological test for detecting an antigen in a sample
SU1698764A1 (en) Method for determining persons, predisposed to respiratory tract diseases
RU2005101339A (en) METHOD FOR DETERMINING THE ENDOTOXIN LEVEL IN A HEMOGLOBIN SOLUTION

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: AU

Ref document number: 2000 11918

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642